These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
8. CpG oligonucleotides improve the protective immune response induced by the licensed anthrax vaccine. Klinman DM; Xie H; Ivins BE Ann N Y Acad Sci; 2006 Oct; 1082():137-50. PubMed ID: 17145935 [TBL] [Abstract][Full Text] [Related]
10. Protective immunization against inhalational anthrax: a comparison of minimally invasive delivery platforms. Mikszta JA; Sullivan VJ; Dean C; Waterston AM; Alarcon JB; Dekker JP; Brittingham JM; Huang J; Hwang CR; Ferriter M; Jiang G; Mar K; Saikh KU; Stiles BG; Roy CJ; Ulrich RG; Harvey NG J Infect Dis; 2005 Jan; 191(2):278-88. PubMed ID: 15609239 [TBL] [Abstract][Full Text] [Related]
11. Responding to a small-scale bioterrorist anthrax attack: cost-effectiveness analysis comparing preattack vaccination with postattack antibiotic treatment and vaccination. Schmitt B; Dobrez D; Parada JP; Kyriacou DN; Golub RM; Sharma R; Bennett C Arch Intern Med; 2007 Apr; 167(7):655-62. PubMed ID: 17420423 [TBL] [Abstract][Full Text] [Related]
12. An overview of adverse events reported by participants in CDC's anthrax vaccine and antimicrobial availability program. Martin SW; Tierney BC; Aranas A; Rosenstein NE; Franzke LH; Apicella L; Marano N; McNeil MM Pharmacoepidemiol Drug Saf; 2005 Jun; 14(6):393-401. PubMed ID: 15717323 [TBL] [Abstract][Full Text] [Related]
13. Immunogenicity and tolerance of ascending doses of a recombinant protective antigen (rPA102) anthrax vaccine: a randomized, double-blinded, controlled, multicenter trial. Gorse GJ; Keitel W; Keyserling H; Taylor DN; Lock M; Alves K; Kenner J; Deans L; Gurwith M Vaccine; 2006 Aug; 24(33-34):5950-9. PubMed ID: 16797805 [TBL] [Abstract][Full Text] [Related]
14. Past, imminent and future human medical countermeasures for anthrax. Baillie LW J Appl Microbiol; 2006 Sep; 101(3):594-606. PubMed ID: 16907809 [TBL] [Abstract][Full Text] [Related]
15. Efficacy of recombinant anthrax vaccine against Bacillus anthracis aerosol spore challenge: preclinical evaluation in rabbits and Rhesus monkeys. Chawla A; Midha S; Bhatnagar R Biotechnol J; 2009 Mar; 4(3):391-9. PubMed ID: 19296443 [TBL] [Abstract][Full Text] [Related]
16. Mouse model characterisation for anthrax vaccine development: comparison of one inbred and one outbred mouse strain. Flick-Smith HC; Waters EL; Walker NJ; Miller J; Stagg AJ; Green M; Williamson ED Microb Pathog; 2005 Jan; 38(1):33-40. PubMed ID: 15652293 [TBL] [Abstract][Full Text] [Related]
17. Comparative vaccine efficacy of different isoforms of recombinant protective antigen against Bacillus anthracis spore challenge in rabbits. Ribot WJ; Powell BS; Ivins BE; Little SF; Johnson WM; Hoover TA; Norris SL; Adamovicz JJ; Friedlander AM; Andrews GP Vaccine; 2006 Apr; 24(17):3469-76. PubMed ID: 16519970 [TBL] [Abstract][Full Text] [Related]
18. Nasal immunization with a dual antigen anthrax vaccine induced strong mucosal and systemic immune responses against toxins and bacilli. Sloat BR; Cui Z Vaccine; 2006 Sep; 24(40-41):6405-13. PubMed ID: 16828937 [TBL] [Abstract][Full Text] [Related]
19. CpG oligodeoxynucleotides adsorbed onto polylactide-co-glycolide microparticles improve the immunogenicity and protective activity of the licensed anthrax vaccine. Xie H; Gursel I; Ivins BE; Singh M; O'Hagan DT; Ulmer JB; Klinman DM Infect Immun; 2005 Feb; 73(2):828-33. PubMed ID: 15664922 [TBL] [Abstract][Full Text] [Related]
20. Potentiation of an anthrax DNA vaccine with electroporation. Luxembourg A; Hannaman D; Nolan E; Ellefsen B; Nakamura G; Chau L; Tellez O; Little S; Bernard R Vaccine; 2008 Sep; 26(40):5216-22. PubMed ID: 18462850 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]